Why Tumoroids Are Essential for Drug Screening

Among the various 3D culture approaches, spheroids and tumoroids have emerged as crucial tools for drug screening in preclinical and early clinical studies.

These models provide a better representation of tumor heterogeneity, cell-cell interactions, and drug penetration dynamics compared to traditional 2D cultures.

Spheroids are formed by self-assembly of cancer cells, mimicking avascular tumor structures, while tumoroids incorporate additional elements of the tumor-microenvironment, including stromal and immune components.

Their ability to preserve functional aspects of tumor biology allows for more accurate prediction of therapeutic efficacy and resistance mechanisms.

By offering a balance between complexity and reproducibility, these models are becoming indispensable for pre-clinical stages in drug development.

What We Offer

Advanced 3D patient-derived models for in-house use

Well-characterized 3D cell culture models across multiple cancer types, generated from both established cell lines and patient-derived tissues.
These models include characterization of the tumor microenvironment and are cultured under optimized conditions designed to closely mimic the primary tumor.

Preclinical Drug Testing - Functional Assays

Our functional ex vivo killing assays use advanced 3D cancer models to help pharma teams reliably evaluate, quantify, and compare drug efficacy across cancer types, treatment candidates, and dose levels – providing standardized, actionable data to support drug development decisions.

Treatment Response
100
80
60
40
20
0
100
Control

Minimal Response: 25

Control

Early Response: 25

Control

Moderate Response : 25

Control

Strong Response: 25

Control
Con trol
60
C1 LD

Early Response: 10

C1 LD

Moderate Response: 25

C1 LD

Strong Response: 25

C1 LD
65
C1 HD

Minimal Response: 5

C1 HD

Early Response: 25

C1 HD

Moderate Response : 25

C1 HD

Strong Response: 25

C1 HD
55
C2 LD

Early Response: 25

C2 LD

Moderate Response : 25

C2 LD

Strong Response: 25

C2 LD
65
C2 HD

Early Response: 15

C2 HDC2 HDC2 HD

Moderate Response : 25

C2 HD

Strong Response: 25

C2 HD
25
C3 LD

Strong Response: 25

C3 LD
25
C3 HD

Strong Response: 25

C3 HD
Drug Candidates
C - candidate, LD - Low dose, HD - High dose

Our workflow

Pharma Brief

01

02

Sample & 3D Model Setup

Candidate Screening

03

04

Report & Selection

Service Request Form

Contact Us